AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer-Reference-Cited by-全球学者库

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Published:2014-06-03 Issue:9 Volume:4 Page:1046-1061
ISSN:2159-8274
Container-title:Cancer Discovery
language:en
Short-container-title:Cancer Discovery

Author:

Cross Darren A.E.,Ashton Susan E.,Ghiorghiu Serban,Eberlein Cath,Nebhan Caroline A.,Spitzler Paula J.,Orme Jonathon P.,Finlay M. Raymond V.,Ward Richard A.,Mellor Martine J.,Hughes Gareth,Rahi Amar,Jacobs Vivien N.,Brewer Monica Red,Ichihara Eiki,Sun Jing,Jin Hailing,Ballard Peter,Al-Kadhimi Katherine,Rowlinson Rachel,Klinowska Teresa,Richmond Graham H.P.,Cantarini Mireille,Kim Dong-Wan,Ranson Malcolm R.,Pao William

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

Cited by 1641 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pantoprazole enhances osimertinib activity by inhibiting autophagy in NSCLC cells and tumor xenografts;2024-02-06

2. Liquid biopsy for the management of NSCLC patients under osimertinib treatment;Critical Reviews in Clinical Laboratory Sciences;2024-02-02

3. Profiling of ERBB receptors and downstream pathways reveals selectivity and hidden properties of ERBB4 antagonists;iScience;2024-02

4. Design, synthesis and antitumor activity of 4-arylamine substituted pyrimidine derivatives as noncovalent EGFR inhibitors overcoming C797S mutation;European Journal of Medicinal Chemistry;2024-02

5. Design, synthesis and biological evaluation of 2-phenylaminopyrimidine derivatives as EGFR inhibitors;Bioorganic & Medicinal Chemistry Letters;2024-02